A four-year review from a rural hospital in the Appalachian region of the United States, published October 17, 2025, describes 21 patients with invasive or clinically significant Aeromonas infections identified between October 2018 and December 2022. Investigators reported 26 isolates overall; six came from blood cultures—most linked to biliary disease—and soft tissue infection was documented in 14 patients. One patient presented with acute cholecystitis. Nine patients underwent 10 procedures, including wound debridement, endoscopic retrograde cholangiopancreatography, percutaneous cholecystostomy, and laparoscopic cholecystectomy. Infections resolved with timely procedures and targeted antibiotics; one patient died of metastatic pancreatic cancer, not from infection. The authors concluded that Aeromonas infections remain uncommon in rural U.S. care but can be severe and require prompt recognition and source control (Surgical Infections, 2025).
Why this matters: although rare, Aeromonas can rapidly progress from localized infection to bacteremia, particularly in biliary disease or water-exposed wounds, making fast, appropriate therapy critical for patient outcomes.
Study findings in context
Aeromonas are gram-negative bacteria that thrive in freshwater and brackish environments and can cause gastrointestinal illness as well as extraintestinal disease, including skin and soft tissue infection (SSTI), hepatobiliary infection, and bacteremia. Large series have shown that invasive disease is more likely in older adults and in those with underlying conditions such as liver disease or malignancy. In a multicenter prospective cohort from Japan, hepatobiliary infections accounted for 73% of Aeromonas cases, and 30-day all-cause mortality was 10%, underscoring the organism’s clinical relevance beyond the gut. That study also found that A. caviae was predominant overall, while A. hydrophila was more common in SSTI, and that cefepime retained reliable activity across isolates. These data help explain the biliary tropism and species patterns seen in the new U.S. rural series and support its emphasis on early source control in biliary disease. (Open Forum Infectious Diseases, 2023; U.S. National Library of Medicine.)
Hepatobiliary involvement has been repeatedly documented in prior literature. A review of 30 cases of acute suppurative cholangitis found Aeromonas in 2.9% of episodes, often in patients with ductal stones or prior biliary instrumentation; outcomes improved markedly with biliary drainage. Similarly, an analysis of 41 hepatobiliary or pancreatic infections highlighted frequent obstruction and immunosuppression, with cholangitis the most common presentation. These observations align with the rural U.S. experience, where blood culture isolates were frequently linked to biliary sources. (American Journal of Gastroenterology; Clinical Infectious Diseases, both via PubMed.)
Species distribution and taxonomy
The U.S. series recovered predominantly A. hydrophila or A. caviae, with smaller numbers labeled as A. sobria and A. veronii. Clinicians should note that “A. sobria” is frequently a phenotypic label that, under modern molecular methods, corresponds to Aeromonas veronii biovar sobria; true A. sobria sensu stricto is rarely implicated in human disease. Accurate speciation matters because susceptibility profiles differ by species and can influence empiric choices. (Clinical Microbiology Reviews; Clinical Infectious Diseases commentary.)
Polymicrobial infection is common
In the rural series, Aeromonas was the sole pathogen in 10 cases; 11 infections were polymicrobial, involving gram-positive cocci, gram-negative rods, and anaerobes. Mixed flora have long been reported in water-exposed wounds and biliary infections, a pattern that supports broad initial coverage and early cultures when immersion injuries or atypical features are present. U.S. guidance for cellulitis notes that cultures are particularly useful in immersion injuries and in immunocompromised hosts—scenarios where Aeromonas and other unusual pathogens may be involved. (CDC clinical guidance on cellulitis, reflecting IDSA recommendations.)
Antibiotic susceptibility and empiric choices
Aeromonas species commonly harbor chromosomal beta-lactamases, conferring intrinsic resistance to ampicillin and often to early-generation cephalosporins. In contemporary cohorts, cefepime and fluoroquinolones typically retain activity, while susceptibility to third-generation cephalosporins and carbapenems varies by setting and species. One recent series in hematologic patients reported high carbapenem resistance, reinforcing the need to tailor therapy to local susceptibility data. In freshwater-associated wounds, expert reviews recommend initial coverage with a fluoroquinolone (e.g., ciprofloxacin or levofloxacin) or a third- or fourth-generation cephalosporin; brackish or saltwater injuries often call for doxycycline plus ceftazidime or a fluoroquinolone. Final therapy should be narrowed once culture and sensitivity results return. (Open Forum Infectious Diseases; BMC Infectious Diseases 2022; IDSA SSTI guideline; PubMed review on aquatic wound management.)
Consistent with these patterns, the rural U.S. team reported commonly using fluoroquinolones, third- or fourth-generation cephalosporins, trimethoprim–sulfamethoxazole, and in some cases doxycycline, with clinical resolution in all documented infections after source control. Their experience aligns with guideline principles that active, culture-directed agents combined with timely procedures drive outcomes. (Surgical Infections, 2025; Infectious Diseases Society of America.)
Procedures and source control
The favorable outcomes in the series mirror prior studies showing that drainage and debridement are pivotal when Aeromonas causes biliary obstruction or deep soft tissue infection. In obstructive cholangitis, endoscopic or percutaneous decompression is associated with improved survival, and in rapidly progressive SSTI, early surgical evaluation is essential. While rare, Aeromonas can cause necrotizing fasciitis; mortality increases sharply with delayed recognition, especially in patients with liver disease or immunosuppression, underlining the importance of rapid escalation when systemic toxicity or bullae are present. (American Journal of Gastroenterology; BMC Musculoskeletal Disorders 2025 case literature; PubMed analyses of Aeromonas necrotizing fasciitis.)
Public-health and clinical takeaways
For clinicians in rural and community hospitals, these findings reinforce several practical steps: consider Aeromonas when evaluating invasive infections with biliary involvement or water-associated wounds; obtain early cultures in immersion injuries or immunocompromised patients; begin empiric therapy that covers likely gram-negative aquatic organisms and possible anaerobes; and prioritize source control through debridement or biliary drainage. According to the CDC, culture collection is appropriate in immersion injuries, and IDSA’s SSTI guideline provides empiric options for aquatic exposures with clear paths to de-escalation as results return. (CDC cellulitis guidance; IDSA SSTI guideline.)
From a systems perspective, the case series highlights diagnostic gaps in routine phenotypic identification. Wider access to MALDI-TOF and, when needed, molecular methods could improve species-level accuracy, which has implications for treatment, given variable resistance across A. caviae, A. hydrophila, A. veronii, and the increasingly recognized A. dhakensis. Continued surveillance is warranted; recent cohort work has described diverse beta-lactamase genotypes and noted that genotype–phenotype correlations for beta-lactams can be inconsistent, making local antibiograms indispensable for stewardship. (Open Forum Infectious Diseases; Clinical Microbiology Reviews.)
What readers should know
Aeromonas infections remain relatively uncommon in the United States but are clinically important because they can be invasive, are often polymicrobial, and may not respond to standard cellulitis regimens directed solely at streptococci or methicillin-susceptible Staphylococcus aureus. People with biliary disease, liver conditions, or recent aquatic exposure are most affected. For suspected cases, early cultures, appropriate empiric coverage for freshwater or brackish exposures, and rapid source control are central to recovery. For general background on managing SSTIs, see the Infectious Diseases Society of America’s guideline, and for clinical scenarios where immersion injuries call for cultures and broader coverage, see CDC guidance for clinicians. (IDSA SSTI guideline; CDC cellulitis guidance.)
Key sources for further reading: Aeromonas cohort with species distribution and resistance patterns (Open Forum Infectious Diseases); hepatobiliary infection reviews linking obstruction and outcomes (American Journal of Gastroenterology; Clinical Infectious Diseases); and a review of antimicrobial choices for aquatic wound infections (PubMed review). For taxonomy and clinical relevance of species labels such as “A. sobria,” see Clinical Microbiology Reviews.
